Biotech investors pray for a takeover miracle
Three of the top five buyouts of 2021 happened in the final quarter, and with biotech stocks hurting many hope that the flurry will continue.
Days of reckoning for immune checkpoint blockers
Can a trial carried out in China back a US approval? Investors in anti-PD-(L)1 players will find out soon enough.
Doomsday for Allakos
If lirentelimab reduces eosinophils in diseases characterised by eosinophil accumulation, why doesn’t it work?
Key big pharma catalysts to kick off 2022
Important breast cancer data will come in the opening months of 2022, and Glaxo and Pfizer are due pivotal RSV results.
Sanofi moves further into next-gen oncology
Sanofi’s latest acquisition sees the group pay $1bn for the private immuno-oncology company Amunix.
Ash 2021 movers – IGM steals the show, for all the wrong reasons
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
Ash 2021 – Sanofi takes its time with fitusiran
Sanofi reckons it has a universal haemophilia therapy on its hands – but first it needs to test a lower dose.
